FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194798981> ?p ?o ?g. }

• W3194798981 endingPage "S298" @default.
• W3194798981 startingPage "S298" @default.
• W3194798981 abstract "Objectives: In New York City, the SARS-CoV2 pandemic epicenter of the United States, the surge of cases predated much of the country by several weeks, leading to changes in practice patterns that have informed decisions made by other medical institutions. As the SARS-CoV2 pandemic unfolded, many professional subspecialty organizations released practice guidelines in order to minimize transmission of COVID-19 and protect vulnerable populations. The impact of modifications to traditional gynecologic cancer treatment is not known. Here, we describe the impact of the SARS-COV2 pandemic on chemotherapy practices for gynecologic cancer during the pandemic surge. Methods: We identified patients age 18 or older at Montefiore Medical Center who had a confirmed or suspected diagnosis of gynecologic cancer and received care between March 16, 2020 and June 7, 2020; these dates reflect a series of executive orders issued by the Governor of New York allowing the State Commissioner of Health to cancel elective procedures at hospitals and ambulatory surgery centers. Clinical data were abstracted from patients’ charts. Patients with incomplete treatment records were excluded. Results: A total of 146 women who were included to whom 169 cycles of cytotoxic chemotherapy were delivered during the study period and 68 women (46.6%) received at least one cycle of chemotherapy. Nine patients screened positive for symptoms of COVID or active infection during the study period. Among patients receiving chemotherapy, 52.9% (n=36) had modifications to traditional cancer treatment as a result of state and institutional regulations. Dose reduction was the leading pandemic-related treatment modification and occurred in 69.4% of patients (n=25). Other treatment modifications included prophylactic use of pegfilgrastim (n=1), and treatment deferral or delay (n=7). Women receiving a platinum-based doublet (n=36) during the study period were more likely to sustain dose reduction in chemotherapy (25%) compared to patients undergoing other regimens (0%). A total of 111 women received at least one dose of disease-modifying therapy during the cohort period including chemotherapy, immunotherapy, anti-angiogenesis agents, hormonal therapy, PARP inhibitors, or investigational agents. Treatments were most often discontinued due to completion of adjuvant therapy (n=5), progression of disease (n=4), or toxicity (n=5). Notably 5 patients chose to defer therapy in the setting of the pandemic surge. Only one patient was identified as receiving neoadjuvant chemotherapy specifically due to COVID pandemic-related restrictions. Conclusions: The SARS-COV2 pandemic has led to modification of current standard chemotherapy delivery for gynecologic malignancies with the shared goal of protecting the most vulnerable populations from COVID infection. The impact of these modifications on cancer specific outcomes is not yet known. Future investigation will focus on identifying whether treatment modification to circumvent iatrogenic immunosuppression compromises oncologic outcomes." @default.
• W3194798981 created "2021-08-30" @default.
• W3194798981 creator A5011503231 @default.
• W3194798981 creator A5017182881 @default.
• W3194798981 creator A5050211296 @default.
• W3194798981 creator A5085683611 @default.
• W3194798981 creator A5087390545 @default.
• W3194798981 creator A5089267515 @default.
• W3194798981 date "2021-08-01" @default.
• W3194798981 modified "2023-09-24" @default.
• W3194798981 title "The impact of the SARS-COV2 pandemic on the delivery of chemotherapy for gynecologic cancer at a tertiary care institution in the United States epicenter" @default.
• W3194798981 doi "https://doi.org/10.1016/s0090-8258(21)01217-8" @default.
• W3194798981 hasPublicationYear "2021" @default.
• W3194798981 type Work @default.
• W3194798981 sameAs 3194798981 @default.
• W3194798981 citedByCount "0" @default.
• W3194798981 crossrefType "journal-article" @default.
• W3194798981 hasAuthorship W3194798981A5011503231 @default.
• W3194798981 hasAuthorship W3194798981A5017182881 @default.
• W3194798981 hasAuthorship W3194798981A5050211296 @default.
• W3194798981 hasAuthorship W3194798981A5085683611 @default.
• W3194798981 hasAuthorship W3194798981A5087390545 @default.
• W3194798981 hasAuthorship W3194798981A5089267515 @default.
• W3194798981 hasBestOaLocation W31947989811 @default.
• W3194798981 hasConcept C116675565 @default.
• W3194798981 hasConcept C121608353 @default.
• W3194798981 hasConcept C126322002 @default.
• W3194798981 hasConcept C127413603 @default.
• W3194798981 hasConcept C147176958 @default.
• W3194798981 hasConcept C159047783 @default.
• W3194798981 hasConcept C17744445 @default.
• W3194798981 hasConcept C177713679 @default.
• W3194798981 hasConcept C199539241 @default.
• W3194798981 hasConcept C2776694085 @default.
• W3194798981 hasConcept C2779134260 @default.
• W3194798981 hasConcept C2780427987 @default.
• W3194798981 hasConcept C2780510313 @default.
• W3194798981 hasConcept C29456083 @default.
• W3194798981 hasConcept C2991842025 @default.
• W3194798981 hasConcept C2994372414 @default.
• W3194798981 hasConcept C3006700255 @default.
• W3194798981 hasConcept C3007834351 @default.
• W3194798981 hasConcept C3008058167 @default.
• W3194798981 hasConcept C524204448 @default.
• W3194798981 hasConcept C60859754 @default.
• W3194798981 hasConcept C61434518 @default.
• W3194798981 hasConcept C71924100 @default.
• W3194798981 hasConcept C89623803 @default.
• W3194798981 hasConceptScore W3194798981C116675565 @default.
• W3194798981 hasConceptScore W3194798981C121608353 @default.
• W3194798981 hasConceptScore W3194798981C126322002 @default.
• W3194798981 hasConceptScore W3194798981C127413603 @default.
• W3194798981 hasConceptScore W3194798981C147176958 @default.
• W3194798981 hasConceptScore W3194798981C159047783 @default.
• W3194798981 hasConceptScore W3194798981C17744445 @default.
• W3194798981 hasConceptScore W3194798981C177713679 @default.
• W3194798981 hasConceptScore W3194798981C199539241 @default.
• W3194798981 hasConceptScore W3194798981C2776694085 @default.
• W3194798981 hasConceptScore W3194798981C2779134260 @default.
• W3194798981 hasConceptScore W3194798981C2780427987 @default.
• W3194798981 hasConceptScore W3194798981C2780510313 @default.
• W3194798981 hasConceptScore W3194798981C29456083 @default.
• W3194798981 hasConceptScore W3194798981C2991842025 @default.
• W3194798981 hasConceptScore W3194798981C2994372414 @default.
• W3194798981 hasConceptScore W3194798981C3006700255 @default.
• W3194798981 hasConceptScore W3194798981C3007834351 @default.
• W3194798981 hasConceptScore W3194798981C3008058167 @default.
• W3194798981 hasConceptScore W3194798981C524204448 @default.
• W3194798981 hasConceptScore W3194798981C60859754 @default.
• W3194798981 hasConceptScore W3194798981C61434518 @default.
• W3194798981 hasConceptScore W3194798981C71924100 @default.
• W3194798981 hasConceptScore W3194798981C89623803 @default.
• W3194798981 hasLocation W31947989811 @default.
• W3194798981 hasLocation W31947989812 @default.
• W3194798981 hasOpenAccess W3194798981 @default.
• W3194798981 hasPrimaryLocation W31947989811 @default.
• W3194798981 hasRelatedWork W3017171836 @default.
• W3194798981 hasRelatedWork W3025176011 @default.
• W3194798981 hasRelatedWork W3027835066 @default.
• W3194798981 hasRelatedWork W3032320397 @default.
• W3194798981 hasRelatedWork W3152606407 @default.
• W3194798981 hasRelatedWork W3195776524 @default.
• W3194798981 hasRelatedWork W4280491013 @default.
• W3194798981 hasRelatedWork W4295235318 @default.
• W3194798981 hasRelatedWork W4308017287 @default.
• W3194798981 hasRelatedWork W3107152225 @default.
• W3194798981 hasVolume "162" @default.
• W3194798981 isParatext "false" @default.
• W3194798981 isRetracted "false" @default.
• W3194798981 magId "3194798981" @default.
• W3194798981 workType "article" @default.